Urology Today.net

Site updated at Thursday, 12 May 2016

Common Urological Problems

Yervoy

Bristol’s Yervoy falls short in prostate cancer study

Bristol-Myers Squibb Co’s immunotherapy drug Yervoy failed to significantly prolong survival among patients with advanced prostate cancer who had previously received chemotherapy, according to limited data from the first late-stage study of the drug for the condition.

Yervoy (ipilimumab) frees the immune system to attack and kill cancer cells by blocking the action of… Bristol’s Yervoy falls short in prostate cancer study   



urs1 - anxiety1 - vitamin e2 - prostate tissue cells1 - uric acid7 - differential diagnosis1 - urinary tract defects1 - urodynamics1 - plos one1 - regional lymph nodes1 - neutrophil gelatinase-associated lipocalin1 - short-term hormone therapy1 - mortality rates1 - renal calculi1 - early-stage prostate cancer2 - urinary incontinence2 - radiation therapy oncology group1 - microrna1 - urogenital sphincter1 - bulbocavernosus reflex1 - nephrotic syndrome4 - antibiotic resistance1 - rectal balloon1 - robot-assisted radical prostatectomy1 - paediatric urology2 - tissue matching1 - non-skin cancer1 - computational biology1 - the american society of nephrology3 - cardiovascular disease5 -